Nicotine salts, co-crystals, and salt co-crystal complexes

Patent metadata

Field	Value
Publication number	US-10556880-B2
Application number	US-201715671722-A
Country	US
Kind code	B2
Filing date	Aug 8, 2017
Priority date	May 27, 2014
Publication date	Feb 11, 2020
Grant date	Feb 11, 2020

Abstract

The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

First claim

What is claimed:

1. A
salt of nicotine and 3,5-dihydroxybenzoic acid, wherein the salt is in an anhydrous form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

2. The salt of claim 1 , wherein at least about 50% of the salt is in crystalline form.

3. The salt of claim 1 , wherein at least about 70% of the salt is in crystalline form.

4. The salt of claim 1 , wherein at least about 80% of the salt is in crystalline form.

5. The salt of claim 1 , wherein at least about 90% of the salt is in crystalline form.

6. The salt of claim 1 , wherein the salt exhibits a discrete melting point with an onset of about 138° C.

7. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at two or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

8. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at three or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

9. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at four or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

10. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at five or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

11. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at six or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

12. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at seven or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

13. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at eight or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

14. The salt of claim 1 , characterized by an X-ray powder diffraction pattern having peaks at all of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.

Assignees

• Reynolds Tobacco Co R

Inventors

• Dull Gary M
• Carr Andrew
• Sharp Emma

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title

• A61P25/34

  Tobacco-abuse · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/26

  Psychostimulants, e.g. nicotine, cocaine · CPC title